Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.

Autor: Acs B; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. balazs.acs@ki.se.; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. balazs.acs@ki.se.; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. balazs.acs@ki.se., Leung SCY; University of British Columbia, Vancouver, BC, Canada., Kidwell KM; Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA., Arun I; Tata Medical Center, Kolkata, West Bengal, India., Augulis R; Vilnius University Faculty of Medicine and National Center of Pathology, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania., Badve SS; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA., Bai Y; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Bane AL; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada., Bartlett JMS; Ontario Institute for Cancer Research, Toronto, ON, Canada.; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom., Bayani J; Ontario Institute for Cancer Research, Toronto, ON, Canada., Bigras G; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada., Blank A; Institute of Pathology, University of Bern, Bern, Switzerland.; Institute of Pathology, Triemli Hospital Zurich, Zurich, Switzerland., Buikema H; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Chang MC; Department of Pathology & Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA., Dietz RL; Department of Pathology, Olive View-UCLA Medical Center, Los Angeles, CA, USA., Dodson A; UK NEQAS for Immunocytochemistry and In-Situ Hybridisation, London, United Kingdom., Fineberg S; Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA., Focke CM; Dietrich-Bonhoeffer Medical Center, Neubrandenburg, Mecklenburg-Vorpommern, Germany., Gao D; University of British Columbia, Vancouver, BC, Canada., Gown AM; PhenoPath Laboratories, Seattle, WA, USA., Gutierrez C; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Hartman J; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden., Kos Z; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Lænkholm AV; Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark., Laurinavicius A; Vilnius University Faculty of Medicine and National Center of Pathology, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania., Levenson RM; Department of Medical Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA., Mahboubi-Ardakani R; Department of Medical Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA., Mastropasqua MG; European Institute of Oncology, Milan, Italy., Nofech-Mozes S; University of Toronto Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Osborne CK; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Penault-Llorca FM; Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Université Clermont Auvergne, INSERM, Clermont-Ferrand, France.; Service de Pathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Piper T; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom., Quintayo MA; Ontario Institute for Cancer Research, Toronto, ON, Canada., Rau TT; Institute of Pathology, University of Bern, Bern, Switzerland.; Institute of Pathology, Heinrich Heine University and University Hospital of Duesseldorf, Duesseldorf, Germany., Reinhard S; Institute of Pathology, University of Bern, Bern, Switzerland., Robertson S; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden., Salgado R; Department of Pathology, GZA-ZNA, Antwerp, Belgium.; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Sugie T; Kansai Medical University, Hirakata, Osaka, Japan., van der Vegt B; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Viale G; European Institute of Oncology, Milan, Italy.; European Institute of Oncology IRCCS, and University of Milan, Milan, Italy., Zabaglo LA; The Institute of Cancer Research, London, United Kingdom., Hayes DF; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Dowsett M; The Institute of Cancer Research, London, United Kingdom., Nielsen TO; University of British Columbia, Vancouver, BC, Canada., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. david.rimm@yale.edu.
Jazyk: angličtina
Zdroj: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2022 Oct; Vol. 35 (10), pp. 1362-1369. Date of Electronic Publication: 2022 Jun 21.
DOI: 10.1038/s41379-022-01104-9
Abstrakt: Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image analysis (DIA) platform to: (i) investigate the comparability of Ki67 measurement across corresponding core biopsy and resection specimen cases, and (ii) assess section to section differences in Ki67 scoring. Two sets of 60 previously stained slides containing 30 core-cut biopsy and 30 corresponding resection specimens from 30 estrogen receptor-positive breast cancer patients were sent to 17 participating labs for automated assessment of average Ki67 expression. The blocks were centrally cut and immunohistochemically (IHC) stained for Ki67 (MIB-1 antibody). The QuPath platform was used to evaluate tumoral Ki67 expression. Calibration of the DIA method was performed as in published studies. A guideline for building an automated Ki67 scoring algorithm was sent to participating labs. Very high correlation and no systematic error (p = 0.08) was found between consecutive Ki67 IHC sections. Ki67 scores were higher for core biopsy slides compared to paired whole sections from resections (p ≤ 0.001; median difference: 5.31%). The systematic discrepancy between core biopsy and corresponding whole sections was likely due to pre-analytical factors (tissue handling, fixation). Therefore, Ki67 IHC should be tested on core biopsy samples to best reflect the biological status of the tumor.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: